Technical Analysis for ALT - Altimmune, Inc.

Grade Last Price % Change Price Change
F 9.92 1.33% 0.13
ALT closed up 5.61 percent on Tuesday, December 7, 2021, on 62 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ALT trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 1.33%
Lower Bollinger Band Walk Weakness 1.33%
Multiple of Ten Bearish Other 1.33%
Oversold Stochastic Weakness 1.33%
Lower Bollinger Band Walk Weakness 7.01%
Below Lower BB Weakness 7.01%
Lower Bollinger Band Touch Weakness 7.01%
Oversold Stochastic Weakness 7.01%
Expansion Breakdown Bearish Swing Setup 4.64%
Lower Bollinger Band Walk Weakness 4.64%
Older End-of-Day Signals for ALT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1 ATR about 22 hours ago
60 Minute Opening Range Breakout about 23 hours ago
Up 5% about 24 hours ago
Up 3% 1 day ago
Rose Above Previous Day's High 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Altimmune, Inc. Description

Altimmune,Inc., formerly Pharmathene, Inc., is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Phosphate Manufacturing Process Vaccine Nerve Reversal Manufacturing Processes Choline Biodefense Biological Warfare Anthrax Chemical Warfare Cholinesterase Anthrax Vaccines Athene

Is ALT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 24.61
52 Week Low 8.1
Average Volume 1,105,849
200-Day Moving Average 12.81
50-Day Moving Average 11.25
20-Day Moving Average 10.47
10-Day Moving Average 10.06
Average True Range 0.58
ADX 42.52
+DI 12.00
-DI 26.79
Chandelier Exit (Long, 3 ATRs) 9.67
Chandelier Exit (Short, 3 ATRs) 10.74
Upper Bollinger Bands 11.56
Lower Bollinger Band 9.38
Percent B (%b) 0.19
BandWidth 20.88
MACD Line -0.50
MACD Signal Line -0.46
MACD Histogram -0.0464
Fundamentals Value
Market Cap 323.77 Million
Num Shares 33.1 Million
EPS -4.16
Price-to-Earnings (P/E) Ratio -2.35
Price-to-Sales 40.41
Price-to-Book 2.12
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.57
Resistance 3 (R3) 10.56 10.28 10.44
Resistance 2 (R2) 10.28 10.08 10.29 10.40
Resistance 1 (R1) 10.04 9.96 10.16 10.05 10.35
Pivot Point 9.76 9.76 9.83 9.77 9.76
Support 1 (S1) 9.52 9.56 9.64 9.53 9.23
Support 2 (S2) 9.24 9.44 9.25 9.18
Support 3 (S3) 9.00 9.24 9.14
Support 4 (S4) 9.01